The estrogen-induced regression of post-menopausal ER+ breast cancer is a paradoxical finding since ER+ breast cancers also respond to estrogen deprivation whether induced through oophorectomy, selective estrogen modulators, aromatase inhibitors or ER downregulation [5]. Here, CYP19A1 is linked to breast cancer.